Search clinical trials for: QR-421a

Total 42 results

ProQR Therapeutics

Terminated

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, United Kingdom
ProQR Therapeutics

Completed

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Stellar)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Canada, France
Quigley Pharma, Inc.

Completed

Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

Diabetic Neuropathy

United States
ProQR Therapeutics

Withdrawn

Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 (Fuchs Focus)

Corneal Diseases | Fuchs Endothelial Corneal Dystrophy | FECD3 | LRS | Descemet's Membrane Disorder

United Kingdom
Phoenicis Therapeutics

Terminated

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Epidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, Dominant

United States, Spain, France
ProQR Therapeutics

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene (AURORA)

Eye Diseases | Retinitis | Eye Diseases, Hereditary | Retinal Dystrophies | Vision Disorders | Retinal Disease | Autosomal Dominant Retinitis Pigmentosa | Vision Tunnel

United States
Kocaeli University

Completed

Preterm Newborn Mothers' Anxiety and Self-Efficacy

Education | Mother-Infant Interaction | Nursing Care

Turkey
ProQR Therapeutics

Terminated

Extension Study to Study PQ-110-001 (NCT03140969) (INSIGHT)

Eye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

United States, Belgium
ProQR Therapeutics
European Commission

Completed

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

Cystic Fibrosis

United States, France, Belgium
ProQR Therapeutics

Recruiting

An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. (BRIGHTEN)

Eye Diseases | Neurologic Manifestations | Retinal Degeneration | Retinal Dystrophies | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

Belgium, Brazil, Canada, Germany, Italy, Netherlands, United Kingdom
ProQR Therapeutics

Completed

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Leber's Congenital Amaurosis

United States, Belgium
ProQR Therapeutics
European Commission

Completed

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

Cystic Fibrosis

United States, Spain, United Kingdom, Germany, Italy, Belgium, Canada, Czechia, Denmark, France
ProQR Therapeutics

Active, not recruiting

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) (ILLUMINATE)

Eye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

United States, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, United Kingdom
Bayer

Completed

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis

Brain Neoplasms

Japan
Sakarya University

Not yet recruiting

Effect of Breastfeeding Training (Breastfeeding)

Breastfeeding

Turkey
Bayer

Completed

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography

Peripheral Vascular Diseases | Peripheral Arterial Diseases | Magnetic Resonance Angiography

Japan
Inovio Pharmaceuticals
GeneOne Life Science, Inc.; Defense Advanced Research Projects Agency

Completed

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Ebola Vaccine

United States
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients (HIV-1)

HIV-1-infection
Addpharma Inc.

Completed

A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B

Hyperlipidemias

Korea, Republic of
United BioPharma
National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho... and other collaborators

Completed

The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

HIV-1 Infection

Taiwan
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir

HIV-1-infection
University of North Carolina, Chapel Hill
American Diabetes Association

Completed

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

Overweight and Obesity | Eating Behavior

United States
University of British Columbia

Completed

Mannitol Cream for Post Herpetic Neuralgia (MannitolPHN)

Neuralgia, Postherpetic

Canada
United BioPharma
Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Veterans... and other collaborators

Completed

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

HIV-1 Infection

Taiwan
United BioPharma

Not yet recruiting

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

HIV-1-infection
United Biomedical
Taipei Veterans General Hospital, Taiwan; Kaohsiung Veterans General Hospital. and other collaborators

Completed

Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults

HIV-1 Infection in Adults

Taiwan
University of British Columbia

Completed

Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy

Canada
United Biomedical

Completed

Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults

HIV-1 Infection in Adults (Asymptomatic)

Taiwan
Beth Kirkpatrick
International Centre for Diarrhoeal Disease Research, Bangladesh

Active, not recruiting

Dengue Controlled Human Infection Model in Dhaka, Bangladesh

Dengue

Bangladesh
National Institute of Allergy and Infectious Diseases...

Recruiting

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

Multi-Drug Resistant Hiv-1 Infection | HIV-1 Infection

United States
Sidekick Health
Landspitali University Hospital; Ljósið Cancer Rehabilitation Center

Active, not recruiting

A Digital Solution for Breast Cancer Patients

Breast Cancer

Iceland
United BioPharma

Withdrawn

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

HIV-1 Infection

China
VeroScience

Completed

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

Type 2 Diabetes

United States
United BioPharma

Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

HIV-1 Infection

Taiwan
United BioPharma
Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaborators

Completed

To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults

HIV-1 Infection

Taiwan
United BioPharma

Not yet recruiting

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

HIV-1 Infection
University of Texas Southwestern Medical Center

Completed

QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
United BioPharma

Not yet recruiting

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

HIV-1 Infection
United BioPharma

Withdrawn

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

HIV-1 Infection
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

Primary Hypercholesterolemia

Korea, Republic of
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

Mucociliary Clearance

United Kingdom
Avekshan LLC

Completed

Study for Naltrexone on the Abuse Potential of Methylphenidate

Naltrexone | Methylphenidate Abuse

United States

Search clinical trials for: QR-421a

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations